New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 24, 2014
06:35 EDTLLYEli Lilly still sees FY14 adjusted EPS $2.72-$2.80, consensus $2.81
Now sees FY14 reported EPS $2.70-$2.78. Sees FY14 revenue $19.4B-$20B, consensus $19.75B. . As described in the company's initial guidance, patent expirations are expected to drive a rapid and severe decline in U.S. Cymbalta and U.S. Evista sales. These revenue declines are expected to be partially offset by growth from a portfolio of other products including Humalog, TrajentaŽ, Cialis, Forteo and Alimta, as well as the animal health business. In addition, strong revenue growth is expected in China, while a weaker Japanese yen will dampen revenue growth in Japan.The company now anticipates that gross margin as a percent of revenue will be approximately 73% in 2014. Total operating expenses in 2014 are expected to decrease substantially compared to 2013. The 2014 tax rate is now expected to be approximately 19%, assuming a full-year 2014 benefit of the R&D tax credit and other tax provisions up for extension. If these items are not extended, the 2014 tax rate would be approximately 2 percentage points higher. The company now expects 2014 net income to be at least $2.9B and still expects operating cash flow to be at least $4B. Operating cash flows are still expected to be sufficient to pay the company's dividend of approximately $2.1B, allow for capital expenditures of approximately $1.3B, and fund certain business development activity and share repurchases. The company's 2014 financial guidance assumes that the acquisition of Novartis Animal Health does not close during this calendar year. Should the acquisition close during 2014, the company will revise its 2014 financial guidance, if necessary.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
13:02 EDTLLYEli Lilly says trial data shows Trulicity effective as add-on treatment
New data from a completed Phase 3 trial show Trulicity 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1C from baseline after 24 weeks of treatment, Eli Lilly said. Trulicity is Eli Lilly's once-weekly glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. These data, from the Trulicity AWARD-8 clinical trial, were presented for the first time today at the 2015 International Diabetes Federation World Diabetes Congress in Vancouver, Canada. "For patients who cannot tolerate or have contraindications to metformin, a sulfonylurea is often prescribed as first-line therapy for type 2 diabetes," said Kathleen Dungan, M.D., endocrinologist, associate professor, The Ohio State University Wexner Medical Center, and lead study author. "This study affirms that Trulicity is efficacious and well-tolerated as an add-on to sulfonylurea therapy, which can help prescribers make treatment decisions for their individual patients."
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Outperform from Neutral at Credit Suisse... Allstate (ALL) upgraded to Neutral from Sell at Citi... Campbell Soup (CPB) upgraded to Buy from Hold at Argus... Cenovus Energy (CVE) upgraded to Neutral from Sell at Goldman... Computer Programs (CPSI) upgraded to Hold from Sell at Deutsche Bank... Concho Resources (CXO) upgraded to Strong Buy from Outperform at Raymond James... Conn's (CONN) upgraded to Buy from Hold at Stifel... Delta Lloyd (DLLLY) upgraded to Neutral from Underweight at JPMorgan... Eli Lilly (LLY) assumed with an Overweight from Equal Weight at Barclays... HF Financial (HFFC) upgraded to Buy from Hold at Sandler O'Neill... Johnson & Johnson (JNJ) upgraded to Overweight from Equal Weight at Barclays... KPN (KKPNY) upgraded to Buy from Neutral at Nomura... Merck (MRK) assumed with an Overweight from Equal Weight at Barclays... Monsanto (MON) upgraded to Overweight from Neutral at Atlantic Equities... Nokia (NOK) upgraded to Outperform from Neutral at Credit Suisse... Parkway Properties (PKY) upgraded to Buy from Hold at Stifel... Pioneer Natural (PXD) upgraded to Strong Buy from Outperform at Raymond James... Rackspace (RAX) upgraded to Outperform from Sector Perform at RBC Capital... TerraForm Power (TERP) upgraded to Outperform from Perform at Oppenheimer... Windstream (WIN) upgraded to Outperform from Market Perform at Raymond James... Yum! Brands (YUM) upgraded to Outperform from Market Perform at Cowen.
09:34 EDTLLYBarclays biopharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
05:43 EDTLLYEli Lilly assumed with an Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Eli Lilly (LLY) to Overweight after assuming coverage of the name. Good execution for Cyramza and Jardiance should drive continued share outperformance, Meacham tells investors in a research note. He raised his price target for shares to $95 from $75. Lilly closed yesterday down $1.43 to $82.22. The analyst this morning also upgraded Johnson & Johnson (JNJ) and Merck (MRK) to Overweight and downgraded AbbVie (ABBV) to Equal Weight.
November 24, 2015
14:43 EDTLLYEli Lilly confirms FDA approval of Portrazza
Subscribe for More Information
11:48 EDTLLYFDA approves Portrazza to treat NSCLC
Subscribe for More Information
November 19, 2015
06:34 EDTLLYEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:11 EDTLLYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:09 EDTLLYValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use